Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019;8(1):219.
Epub 2019 Apr 12.

Product Labeling of Drugs Commonly Administered to Children and Adults with Obesity

Kanecia O Zimmerman  1   2 , Daniel K Benjamin Jr  1   2 , Mara L Becker  3 , Ravinder Anand  4 , Christoph P Hornik  1   2
Affiliations

Product Labeling of Drugs Commonly Administered to Children and Adults with Obesity

Kanecia O Zimmerman et al. Pharm Regul Aff. 2019.

Abstract

Obesity is a major public health problem that can affect drug disposition and dosing, particularly in vulnerable pediatric populations. Despite potentially detrimental consequences from inappropriately dosed drugs in children with obesity, drug product labels largely fail to include dosing or guidance specific to this population. Failure to include this information results in an increased incidence of adverse events, and concerns from treating physicians regarding their ability to provide appropriate care for children with obesity. Using data from the National Institute of Child Health and Human Development-funded Pediatric Trials Network (PTN), we explore possible ways to improve drug labeling in children with obesity. In order to improve health outcomes of children with obesity, carefully designed and executed PK trials and comprehensive PK analysis strategies are needed. Early collaboration with the Food and Drug Administration may be helpful in developing studies and analyses that are most beneficial for child health. This collaboration is particularly important for drugs that treat potentially life-threatening diseases, where inclusion of PK and dosing on the drug label is vital. We hope that increasing the body of knowledge on drug dosing in children with obesity will open the door to regulatory guidance based on extrapolation or population-specific PK studies, similar to other currently-recognized special populations. Given the magnitude of the pediatric obesity pandemic, recognition as a special population will offer substantial public health value.

Keywords: drug dosing; obese children; pharmacokinetic data.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest All authors report no relevant conflicts of interest.

Figures

Figure 1.
Figure 1.. Obesity-associated Effects
The effect of obesity on various bodily functions.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. World Health Organization (WHO). Global strategy on diet, physical activity and health. Childhood overweight and obesity. WHO web site. http://www.who.int/dietphysicalactivity/childhood/en/. Accessed September 25, 2018.
    1. Centers for Disease Control and Prevention (CDC). Defining childhood obesity. CDC web site. https://www.cdc.gov/obesity/childhood/defining.html. Updated October 20, 2016. Accessed January 10, 2019.
    1. Ogden CL, Carroll MD, Lawman HG, Fryar CD, Kruszon-Moran D, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988–1994 through 2013–2014. JAMA. 2016; 315:2292–2299. - PMC - PubMed
    1. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005; 44:1051–1065. - PubMed
    1. Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol. 1984; 18:941–946. - PMC - PubMed

LinkOut - more resources